[go: up one dir, main page]

EP2185235B1 - Dispositif de réduction de poids - Google Patents

Dispositif de réduction de poids Download PDF

Info

Publication number
EP2185235B1
EP2185235B1 EP08787502.7A EP08787502A EP2185235B1 EP 2185235 B1 EP2185235 B1 EP 2185235B1 EP 08787502 A EP08787502 A EP 08787502A EP 2185235 B1 EP2185235 B1 EP 2185235B1
Authority
EP
European Patent Office
Prior art keywords
electrodes
generator
individual
during
vagus nerve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP08787502.7A
Other languages
German (de)
English (en)
Other versions
EP2185235A2 (fr
Inventor
Eric Bobillier
Charles-Henri Malbert
Arnaud Biraben
David Val-Laillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Recherche Agronomique INRA
Centre Hospitalier Universitaire de Rennes
Original Assignee
Institut National de la Recherche Agronomique INRA
Centre Hospitalier Universitaire de Rennes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Recherche Agronomique INRA, Centre Hospitalier Universitaire de Rennes filed Critical Institut National de la Recherche Agronomique INRA
Publication of EP2185235A2 publication Critical patent/EP2185235A2/fr
Application granted granted Critical
Publication of EP2185235B1 publication Critical patent/EP2185235B1/fr
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36007—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of urogenital or gastrointestinal organs, e.g. for incontinence control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
    • A61N1/36114—Cardiac control, e.g. by vagal stimulation

Definitions

  • the present description relates to a method for reducing weight through vagus nerve stimulation and to a device for use in such treatment.
  • the invention is set out in the appended claims.
  • Obesity is one of the largest health problems in the western countries. It may lead to numerous secondary pathology, such as diabetes, sleep apnea, heart diseases, pulmonary diseases; osteoarthritis.
  • the aetiology of obesity is always multifactorial, including genetic and environmental factors. The ideal treatment of obesity is not yet available.
  • VNS Vagus Nerve Stimulation
  • WO 02/062291 describes a method and device for treating obesity in an individual through sub-diaphragmatic vagus nerve stimulation with an electrical pulse signal.
  • a device for reducing weight in an individual comprising a generator adapted to produce an electrical signal and at least a first set of electrodes comprising two electrodes able to be connected to the generator, the electrodes being intended to be fixed to a first vagus nerve of the individual at a predefined distance one from another, to apply the electrical signal to a portion of the first vagus nerve located between the electrodes.
  • the present description relates to a device for reducing weight in an individual, the device comprising:
  • the present description also relates to a device as defined above as a surgical implant for reducing weight in an individual.
  • the present description also relates to a method for reducing weight in an individual, wherein an effective electrical signal is applied peri-diaphragmatically to a portion of a first vagus nerve and optionally to a portion of a second vagus nerve, wherein the electrical signal is in the form of pulses trains, the pulses having amplitudes increasing from 0.1 milliampere to 2.5 milliampere during a progressive phase (PP) and a constant amplitude equal to 2.5 milliampere during a stabilised phase (SP).
  • PP progressive phase
  • SP stabilised phase
  • the present description further relates to a method for reducing weight in an individual, wherein an effective electrical signal is applied peri-diaphragmatically to a portion of a first vagus nerve and optionally to a portion of a second vagus nerve by at least one device as defined above.
  • the present description also relates to the use of a device as defined above, for the manufacture of a surgical implant intended for reducing weight in an individual.
  • reducing weight in an individual relates to a reduction of the fat tissues of the individual.
  • the individual may or may not suffer from obesity. If the individual suffers from obesity, in particular from morbid obesity, then the method amounts to a method for treating obesity. This expression also encompasses a reduction in weight increase.
  • obesity relates to a condition characterized by an excess body weight of an individual with respect to the individual's size, as compared to a normal individual.
  • BMI Body Mass Index
  • Individuals with a BMI of 35-40 of greater will be said to be severely obese or morbidly obese.
  • the device, methods and use according to the description can be applied to any individual whose body weight, in particular fat body weight, needs to be reduced, be not considered obese or non-obese.
  • the methods of the description should not be considered as therapeutic methods but merely as non-therapeutic methods or aesthetic methods.
  • weight-related diseases or obesity-related pathologies relates to pathologies which aetiologies comprise excess weight or obesity. Such pathologies may notably encompass type 2 diabetes, sleep apnea, heart diseases, pulmonary diseases, or osteoarthritis.
  • ⁇ preferably relates to a mammal, in particular a human.
  • vagus nerve designates the cranial nerve X and its various branches.
  • the “first vagus nerve” and the “second vagus nerve” are selected from the ventral vagus nerve (which innervates in part the stomach, the liver and the proximal duodenum) and the dorsal vagus nerve (which innervates in part the stomach and gets lost in the celiac ganglia).
  • an effective electrical signal is applied to both the first and second vagus nerves
  • peripherally designates a portion of the vagus nerve which is located next to the diaphragm, either supra-diaphragmatically or sub-diaphragmatically.
  • this portion is located from 1 cm to 2 cm below diaphragm level for the sub-diaphragm position. This position corresponds to a part of the vagus nerve which can be easily freed from connective tissues.
  • the portion is preferably from 1 cm to 2 cm above the diaphragm. This position corresponds to the part of the vagus nerve located immediately above the Plexus gastricus cranialis.
  • the expression "effective electric signal” relates to a signal which characteristics (such as intensity, amplitude, pulse duration, frequency) enable a reduction of body weight or of body weight increase.
  • the surgical methodology for implanting the device according to the description or for vagus nerve stimulation is well known to one of skill in the art and may follow that described e.g. by S.A. Reid ("Surgical technique for implantation of the neurocybernetic prothesis.” Epilepsia 31:S38-S39, 1990 ) for epilepsy treatment.
  • the device is implanted in a left subclavian area of the individual.
  • the medical device 2 is a vagus electro-stimulator device. It comprises an electronic unit 4, a first 6 and second 8 sets of insulated electrodes/leads connected to the electronic unit 4.
  • the two sets of electrodes 6, 8 are connected to a single electronic unit 4 included in a box.
  • the box is made of titanium.
  • the box is surgically implanted in a subcutaneous pocket of a left subclavian area of the individual.
  • the first set 6 comprises a first 10 and a second 12 electrodes having distal ends respectively 14 and 16.
  • the distal ends 14 and 16 are intended to be fixed to the dorsal vagus nerve 18 at a predefined distance one from another to apply a current signal to a portion 19 of the dorsal vagus nerve 18 located between these distal ends.
  • the proximal ends of the first set 6 are linked to output connectors 20, 22 of the electronic unit 4.
  • the second set 8 comprises a first 24 and a second 26 electrodes having distal ends respectively 28 and 30 intended to be fixed to a ventral vagus nerve 32 at a predefined distance one from another to apply the current signal to a portion 33 of the ventral vagus nerve 32 located between these distal ends.
  • the proximal ends of the second set 8 are connected to output connectors 34, 36 of the electronic unit 4.
  • the distal ends 14, 16, 28, 30 of the electrodes are positioned in an area between the top part of the stomach 38 and the lower part of the diaphragm 40.
  • the electrodes 10, 12, 24, 26 are placed surgically using minimal invasive procedure for the nerves shield surrounding the dorsal and the ventral vagus nerves either immediately before or after the diaphragm 40.
  • the electronic unit 4 comprises a voltage generator 42, a voltage current converter 43, a digital-to-analogue converter 44 and a microprocessor 46 connected to the digital-to-analogue converter 44.
  • the voltage generator 42 is a rechargeable battery.
  • the voltage current converter 43 comprises a transistor 45 adapted to be linked to the voltage generator 42, an amplifier 47 connected to the transistor 45 and a resistance 49 connected to the transistor 45.
  • the transistor 45 is an n-channel Bipolar Junction Transistor (BJT). It has a base connected to the output of the amplifier 47 via a resistance 82, an emitter linked to the resistance 49, and a collector adapted to be connected to one terminal of the voltage generator 42, the other terminal of the voltage generator being connected to a ground 53.
  • BJT Bipolar Junction Transistor
  • the amplifier 47 has a negative input connected by a line 55 to the resistance 49 and to the emitter of the transistor 45, and a positive input linked to the digital-to-analogue converter 44.
  • the voltage current converter 43 comprises a terminal 51 linked to the resistance 49.
  • the terminal 51 is set at a predetermined positive voltage of 1.5 V.
  • the voltage current converter 43 operates as well known in the state of the art.
  • the voltage generator 42 and the voltage current converter form a current generator hereafter referenced 42, 43.
  • the current generator 42, 43 is adapted to apply a current signal to the portion 19 of the dorsal vagus nerve 18 and to the portion 33 of the vagus nerve 32.
  • the portions of the vagus nerves 19, 33 located between the distal ends 14, 16 and 28, 30 constitute a load for the current generator 42, 43. This load can vary along the time.
  • the current generator 42, 43 is able to adapt the voltage applied to the portions 19 and 33 of the vagus nerves (i.e. load) such as to maintain the amplitude of the current signal approximately constant between the distal ends 14, 16 of the first set and between the distal ends 28, 30 of the second set.
  • the digital-to-analogue converter 44 is adapted to convert the digital commands of the microcontroller 46 into analogue ones, as well known.
  • the microprocessor 46 comprises a memory 48 which stores a computer programme defining the current supply commands to the current generator 42, 43.
  • the microprocessor 46 is able to transmit these commands to the amplifier 47 via the digital-to-analogue converter 44.
  • the electronic unit 4 also comprises an RF emitter/receiver 49 to send and receive data to and from a handheld programming device, e.g. to amend the computer programme stored in the memory 48.
  • the electronic unit 4 further comprises a channel selector switch 50 connected to the voltage generator 42, to the terminal 51 and to the microprocessor 46; a short-circuiting switch 52 linked to the channel selector switch 50 and to the output connectors 20, 22, 34, 36 ; and a no compliance detector 54 connected to the microprocessor 46, to the voltage generator 42 and to the terminal 51.
  • the channel selector switch 50 comprises an input 56 for receiving the current signal of the current generator 42, 43, an output 57 connected to the collector of the transistor 45, two lines 58, 60 connected to the output connectors 20 and 22 for current supplying the dorsal vagus nerve 18, and two lines 62, 64 connected to the output connectors 34 and 36 for current supplying the ventral vagus nerve 32.
  • the channel selector switch 50 further comprises two resistances having high impedance and not illustrated in figure 2 .
  • the channel selector switch 50 is adapted to connect alternatively the input 56 and the output 57 to the lines 58, 60, to the lines 62, 64 and to the resistances according to the commands received from the microcontroller 46.
  • the channel selector switch 50 has two contacts not illustrated which are able to select three different electrical terminals noted 1, 2 and 3.
  • the current generator 42, 43 is linked to the resistances. This corresponds to a high impedance connection.
  • the current generator 42, 43 is linked to the lines 58 and 60.
  • the electrodes 10 and 12 supply a current signal to the portion 19 of the dorsal vagus nerve.
  • the current generator 42, 43 is linked to the lines 62 and 64.
  • the electrodes 24 and 26 supply a current signal to the portion 33 of the ventral vagus nerve.
  • the microcontroller 46 is adapted to control the channel selector switch 50 such that the current signal is supplied to the electrodes 10, 12 and the electrodes 24, 26 only during specific periods as described hereafter.
  • the short-circuit switch 52 comprises a first n channel MOSFET transistor 66 in depletion mode, a second n channel MOSFET transistor 68 in depletion mode.
  • the first MOSFET transistor 66 has a gate D connected to the output line 58, a source S connected to the output line 60 and a gate connected to a ground 70 through a line 72.
  • the second MOSFET transistor 68 has a gate D connected to the output line 62, a source S connected to the output line 64 and a gate connected to the ground 70 through the line 72.
  • Each transistor 66, 68 is configured so that when the potential difference (voltage) between its gate and its source is lower than a predefined threshold, the transistor 66, 68 is turned on, namely the transistor 66, 68 is in a passing current status.
  • the two electrodes 10, 12 (or the electrodes 24, 26) are shortcircuited.
  • the transistor 66, 68 When the potential difference between its gate and its source is greater than this predefined threshold, the transistor 66, 68 is turned off. There is an open circuit between the two electrodes 10, 12 (or the electrodes 24, 26).
  • the no compliance detector 54 comprises a first 76 and a second 78 transistors. These transistors are n-channel Bipolar Junction Transistors (BJT).
  • BJT Bipolar Junction Transistors
  • the first transistor 76 is a pnp transistor. It comprises an emitter connected to the output of the amplifier 47 and to the base of the transistor 45 via the resistance 82, a base linked to the base of the transistor 45 via a resistance 84, and a collector connected to the base of the second transistor 78 through a resistance 86.
  • the second transistor 78 comprises a base, an emitter connected to the ground 87, and a collector connected to the microprocessor 46 and to a voltage source 88 through a resistance 90.
  • the current generator 42, 43 attempts to compensate this insufficiency by increasing the current signal circulating from the base to the collector of the transistor 45.
  • the voltage between the terminals of the resistance 82 increases and the current signal passing through the collector and the emitter of the first transistor 76 increases.
  • the current signal delivered by the base of the second transistor 78 increases causing a current signal to be transmitted from the voltage source 88 to the ground 87.
  • the microcontroller 46 is adapted to detect the appearance of this current signal and to generate an alarm. This alarm reflects the fact that the electronic unit 4 is operating under non compliance conditions i.e a current signal having a abnormal elevated amplitude is delivered to the vagus nerves.
  • the alarm can also be generated when one of the electrodes 8, 10 , 24, 26 is cut.
  • the present description also concerns a method for reducing weight wherein an effective current signal is delivered to the vagus nerves along time according to a predefined method which is implemented in the computer program stored in the memory 48.
  • the amplitude of the current signal applied to the mammal body increases gradually during an initial phase, hereafter named progressive phase PP, and is maintained constant during a permanent phase, hereafter named stabilised phase SP, illustrated in figure 3 .
  • the progressive phase PP lasts between 10 and 20 days during which the amplitude increases from 0.1 milliampere to 2.5 milliampere.
  • the progressive phase PP lasts 15 days during which the amplitude increases from 0.1 milliampere to 2.5 milliampere so that the amplitude of the current signal increases each day from 0.16 milliampere.
  • the stabilised phase SP is preferably maintained until treatment of the individual interrupted.
  • the amplitude of the current signal is maintained equal to 2.5 milliampere during the stabilised phase SP.
  • the progressive phase PP and the stabilised phase SP comprise emission periods T1 which last each 30 seconds and non emission periods T2 which last each 5 minutes.
  • the contacts of the selector switch 50 switch from terminal 2 to terminal 3 at a frequency of 60 Hz.
  • the current signal generator 42, 43 provides current signal alternatively to the electrodes 10, 12 (channel A in Figure 4 ) and to the electrodes 24, 26 (channel B in Figure 4 ).
  • the gate of transistor 66, 68 is linked to the voltage generator 42 and the source of this transistor is linked the terminal 51, the potential difference between the gate and the source of this transistor is greater than the predetermined threshold.
  • the transistor 66, 68 is turned off.
  • the electrodes 10 and 12 are not short- circuited.
  • the current generator 42, 43 connected to a single battery provides current to both channel A via the first set of electrodes 6 and to channel B via the second set of electrodes 8. Consequently, a pulse is never simultaneously delivered to both vagus nerves, as schematically illustrated with dotted lines in figure 4 .
  • the dorsal 18 and the ventral 32 vagus nerves are never stimulated simultaneously but one after another such that no linkage current appears between the portion 19 of the dorsal vagus nerve 18 and the portion 33 of the ventral vagus nerve 32.
  • linkage current signals are damageable. They appear when the impedance of the portion 19 of the dorsal vagus nerve is different from the impedance of the portion 33 of ventral vagus nerve. In this case, a potential difference appears between the portion 19 of the dorsal vagus nerves and the portion 33 of the ventral vagus resulting in the emergence of a current between the dorsal vagus nerve and the ventral vagus nerve.
  • the current signal generated during the emission period T1 is formed of pulses trains, as schematically illustrated in figure 4 .
  • An enlarge view of two consecutive pulses is illustrated in figure 5 .
  • the duration L of each pulse is equal to 1 millisecond.
  • the duty cycle of one period of the current signal is equal to 1/30.
  • the period P defined between two consecutive pulses is equal to 33 milliseconds.
  • the contacts of the selector switch 50 are connected to the terminal 1. No current signal is provided to the electrodes 10, 12 or to the electrodes 24, 26.
  • the device avoids the appearance of linkage currents between nerves connected to a stimulation device, when the device does not stimulate these nerves.
  • the described embodiment of the invention needs less energy because the non emission periods T2 are longer than the emission periods T1.
  • classical MOSFET transistor can also be used in the short-circuit switch 52.
  • the device can be implemented with a voltage generator instead of the current generator 42, 43.
  • a voltage signal is applied to the vagus nerves.
  • the device as defined above is a single-use device.
  • a single-use device is a device which can only be implanted once, i.e. the device can not be implanted in a second individual after it has been implanted in a first individual.
  • surgical implants are generally only proper for a single use because they may have been damaged or worn during their implantation period in the first individual (i.e. the surgical implants have been consumed by their use) or because they have been in contact with tissues or fluids of the first individual, which renders their use in a second individual hazardous due to possible contaminations.
  • VNS group Vagal Nerve Stimulation
  • Sham group One group of pigs without VNS, having the same surgical procedure.
  • the pigs were large white females about 3 months old and 35 kg weigh at the beginning of the experiment.
  • Surgery was performed under general anaesthesia, after a few days of acclimatization of the animals to their cage.
  • the electrodes were implanted immediately above the diaphragm. The stimulation was applied bilaterally on the ventral and dorsal vagus nerves. Electrodes implantation with bipolar leads required a thoracotomy with the ablation of the left 8 th cost; both of the bipolar VNS leads (Cyberonics) were coupled with a device according to the description.
  • each animal had a week for recovering, followed by a week of measures without stimulation. Stimulation was then started in the stimulated group.
  • the parameters of stimulation with the exception of output current intensity were kept unchanged during the entire duration of the experiment (frequency of pulses within the trains, 30 Hz; pulse duration, 1 ms; duration of the train, 30 seconds; and frequency of the trains, 300 s). These values are similar to those usually used in human for epilepsy treatment.
  • the output current intensity was increased gradually starting at 0.25 mA and ending at 2.5 mA, so that the amplitude increased of 0.16 mA each day.
  • the animals were fed once every day at the same time and in the same conditions. Access to food was ad libitum for half an hour; the quantity of food (2.2 kg) provided was more than the maximal usual ration for pigs of this age and size. The changes in the weight of the pigs were measured as well as other parameters measured on line during the meal, using a weight gauge located under the animal trough: amounts of food consumed at 10 minutes, 20 minutes and 30 minutes and the ingestion speed.
  • Table 1 Differences in total amount ingested during a meal and in ingestion speed between the sham and VNS groups. Ingested denotes the amount of meal ingested 10, 20 and 30 minutes after the onset of the meal. * denotes a significant difference between groups at p ⁇ 0.05 (one way ANOVA) Data are mean ⁇ SE.
  • EXAMPLE 2 Efficacy of the device and method for altering food preference.
  • VNS group Vagal Nerve Stimulation
  • VNS group Vagal Nerve Stimulation
  • the animals were feed three times daily (9H30, 12H00 and 16H30) for 30 minutes each.
  • the animal has access to three different meals presented in three troughs randomly selected by a dedicated robotic device. This device supplies exactly 600 g of food in each trough so that for each individual meal the animal has the possibility to eat up to 1800 g.
  • the meals were different in their composition: one being identical to standard pig food (Control), the other being enriched in sucrose and the last one being enriched with animal and vegetal fat.
  • the composition of each meal is summarized in Table 2.
  • Vagal nerve stimulation was effective to reduce food intake. However, this might be the result of a slow down in gastric emptying. This reduced emptying in turn is able to induce an increased sensation of fullness which is known to reduce ingestion. This, if it is true, will be damageable to the proposed device and method because in human's gastric stasis aside from being capable to reduce food intake generates epigastric fullness and pain. Therefore, the inventors aimed at demonstrating that the proposed device and method were able to reduce food intake without altering the normal gastric emptying process.
  • VNS group Vagal Nerve Stimulation
  • VNS group Vagal Nerve Stimulation
  • 4 pigs without VNS having the same surgical procedure. These animals were different from those used for Examples 1 and 2. However, the surgical preparation and vagal nerve stimulation procedure were identical to that previously described.
  • EXAMPLE 4 Efficacy of the device and method in adult obese individuals
  • the inventors have designed another experiment involving (1) adult animals instead of pre-pubertal ones and (2) obese animals instead of lean ones. Furthermore, vagal stimulation and surgery were performed in morbidly obese animals to be as close as possible to the pathological setting of the human patients the device and method of the description can be applied to.
  • Two groups of four miniature pigs (Gottingen mini-pigs, 41.9 ⁇ 1.3 kg initially, 18 months at the beginning of the experiment) were feed ad libitum with a western diet supplying energy in excess by 2.5 times the normal requirement during 4 months. After this period, the animals weighted 66.2 ⁇ 4.8 kg and were in a morbid obese state as indicated by insulin and glycemia concentrations.
  • Example 1 Once in a morbid obese situation, four animals were fitted with dual vagal electrodes as indicated in Example 1 connected to two devices according to the invention placed under the skin. The four remaining animals received a sham surgery and two mock devices of the same size and weight as the workings ones were also placed under the skin.
  • Example 1 One week after surgery, the devices were powered on as indicated in Example 1 . During 15 weeks, the weight and diet consumption of the animals were monitored. The animals received the same western diet ad libitum as before during this experimental period.
  • vagal stimulation are statistically different between the groups 6 weeks after the onset of neurostimulation ( Figure 6 ).
  • the weight difference between the two groups is getting more important along the time course of stimulation.
  • the sham group weights more than their reference weight defined as the weight at week zero (p ⁇ 0.05). This effect does not vanish during the entire experimental period which lasts 15 weeks.
  • vagal stimulated group is less than control group starting at week 2 after the onset of the neurostimulation (p ⁇ 0.05, Figure 7 ). This effect does not vanish during the entire experimental period which lasts 15 weeks.
  • VNS Vagal Nerve Stimulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Electrotherapy Devices (AREA)

Claims (12)

  1. Dispositif implantable (2) pour réduire le poids d'un individu, le dispositif (2) comprenant :
    - un générateur de courant (42, 43) conçu pour produire un signal électrique ;
    - une mémoire ;
    - au moins un premier ensemble d'électrodes (6) comprenant deux électrodes (10, 12) conçues pour être connectées au générateur (42, 43) et configurées de manière à être fixées à un nerf pneumogastrique dorsal (18) de l'individu à une distance prédéfinie l'une de l'autre pour appliquer le signal électrique à une partie (19) du nerf pneumogastrique dorsal (18) située entre les électrodes (10, 12) ;
    - un commutateur de mise en court-circuit (52) conçu pour être fermé de manière à court-circuiter les électrodes (10, 12), dans lequel
    - le signal électrique appliqué est un signal de courant efficace qui a une amplitude définie par un procédé mis en oeuvre dans un programme d'ordinateur mémorisé dans la mémoire (48), ladite amplitude augmentant graduellement pendant une phase progressive (PP) et étant maintenue constante pendant une phase stabilisée (SP),
    - le dispositif comprend un deuxième ensemble d'électrodes (8) comprenant deux électrodes (24, 26) conçues pour être connectées au générateur (42, 43) et configurées de manière à être fixées à un nerf pneumogastrique ventral (32) du corps de l'individu à une distance prédéfinie l'une de l'autre pour fournir un courant à une partie (33) du nerf pneumogastrique ventral (32) située entre les électrodes (24, 26) ;
    - le dispositif comprend un commutateur de sélecteur de canal (50) conçu pour connecter alternativement le premier ensemble d'électrodes (6) et le deuxième ensemble d'électrodes (8) au dit générateur (42, 43) conformément à une fréquence prédéfinie pour transmettre le courant généré par ledit générateur (42, 43) alternativement aux nerfs pneumogastriques dorsal (18) et ventral (32),
    - chaque phase comprend une période d'émission (T1) suivie d'une période de non émission (T2),
    - le générateur est conçu pour produire des impulsions pendant chaque période d'émission (T1), et pour ne pas produire d'impulsions pendant les périodes de non émission (T2),
    - le commutateur de mise en court-circuit court-circuite les électrodes des premier et deuxième ensembles pendant la période de non émission (T2), et
    - pendant la période d'émission (T1), le commutateur de sélecteur de canal connecte alternativement le premier ensemble d'électrodes et le deuxième ensemble d'électrodes au dit générateur conformément à la fréquence prédéfinie pour transmettre le courant généré par ledit générateur alternativement aux nerfs pneumogastriques dorsal et ventral.
  2. Dispositif (2) selon la revendication 1, dans lequel le commutateur de mise en court-circuit (52) comprend un transistor MOSFET ayant une grille connectée à une masse (70), une grille (D) reliée à une électrode (10) et une source (S) connectée à l'autre électrode (12).
  3. Dispositif (2) selon la revendication 2, comprenant en outre un générateur de tension (42, 50) conçu pour appliquer une tension à la source (S) du commutateur de mise en court-circuit (52) pour commander sa fermeture et son ouverture.
  4. Dispositif (2) selon l'une quelconque des revendications 1 à 3, dans lequel le générateur (42, 43) est conçu pour ajuster la tension appliquée au moins à la partie (19) du nerf pneumogastrique dorsal (18), et dans lequel le dispositif (2) comprend un détecteur (54) conçu pour générer une alarme lorsque l'amplitude du courant est supérieure à un seuil prédéfini.
  5. Dispositif (2) selon l'une quelconque des revendications 1 à 4, dans lequel le générateur (42, 43) est conçu pour produire des trains d'impulsions, les impulsions ayant des amplitudes augmentant de 0,1 milliampère à 2,5 milliampères pendant la phase progressive (PP) et une amplitude constante égale à 2,5 milliampères pendant la phase stabilisée (SP).
  6. Dispositif (2) selon la revendication 5, dans lequel la phase progressive (PP) est une phase initiale qui dure entre 10 et 20 jours.
  7. Dispositif (2) selon la revendication 5 ou 6, dans lequel les trains d'impulsions ont une période de 33 millisecondes et l'impulsion (L) dure 1 milliseconde.
  8. Dispositif (2) selon la revendication 7, dans lequel la période d'émission (T1) dure 30 secondes et la période de non émission (T2) dure 5 minutes.
  9. Dispositif (2) selon l'une quelconque des revendications 1 à 8, dans lequel l'individu est un individu obèse.
  10. Implant chirurgical destiné à réduire le poids d'un individu, comprenant un dispositif implantable selon l'une quelconque des revendications 1 à 9.
  11. Implant chirurgical selon la revendication 10, dans lequel l'individu est obèse.
  12. Implant chirurgical selon la revendication 10 ou 11, dans lequel l'individu est morbidement obèse.
EP08787502.7A 2007-08-28 2008-08-27 Dispositif de réduction de poids Not-in-force EP2185235B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2007/002466 WO2009027755A1 (fr) 2007-08-28 2007-08-28 Dispositif et procédé de réduction de poids
PCT/EP2008/061204 WO2009027425A2 (fr) 2007-08-28 2008-08-27 Dispositif et procédé de réduction de poids

Publications (2)

Publication Number Publication Date
EP2185235A2 EP2185235A2 (fr) 2010-05-19
EP2185235B1 true EP2185235B1 (fr) 2016-03-16

Family

ID=38924599

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08787502.7A Not-in-force EP2185235B1 (fr) 2007-08-28 2008-08-27 Dispositif de réduction de poids

Country Status (10)

Country Link
US (1) US20100280569A1 (fr)
EP (1) EP2185235B1 (fr)
JP (2) JP5693225B2 (fr)
AU (1) AU2008292174B2 (fr)
CA (1) CA2697622C (fr)
DK (1) DK2185235T3 (fr)
IL (1) IL204110A (fr)
NZ (1) NZ583619A (fr)
WO (2) WO2009027755A1 (fr)
ZA (1) ZA201001287B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
WO2009029614A1 (fr) * 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Dispositifs et procédés permettant d'inhiber l'activation de granulocytes par stimulation neurale
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (fr) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Méthodes et systèmes de réduction d’une inflammation par neuromodulation de l’activité des lymphocytes t
US8412338B2 (en) 2008-11-18 2013-04-02 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US8996116B2 (en) * 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
JP5816408B2 (ja) * 2009-11-13 2015-11-18 オリンパス株式会社 神経刺激装置
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (fr) 2013-04-10 2014-10-16 Setpoint Medical Corporation Stimulation de nerf vague en boucle fermée
EP2515996B1 (fr) 2009-12-23 2019-09-18 Setpoint Medical Corporation Dispositifs de stimulation neurale et systèmes pour le traitement d'une inflammation chronique
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
EP2707094B1 (fr) 2011-05-09 2016-02-03 Setpoint Medical Corporation Activation d'impulsions uniques de la voie anti-inflammatoire cholinergique pour traiter l'inflammation chronique
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
WO2016046587A1 (fr) 2014-09-23 2016-03-31 Inria Institut National De Recherche En Informatique Et En Automatique Procédé et dispositif pour la stimulation de neurones vagaux de petit diamètre myélinisés et non myélinisés
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127756A1 (fr) 2016-01-20 2017-07-27 Setpoint Medical Corporation Commande de stimulation vagale
WO2017127758A1 (fr) 2016-01-20 2017-07-27 Setpoint Medical Corporation Microstimulateurs implantables et systèmes de recharge par induction
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
WO2019036470A1 (fr) 2017-08-14 2019-02-21 Setpoint Medical Corporation Test de dépistage pour stimulation du nerf vague
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
AU2020272128B9 (en) 2019-04-12 2025-11-20 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
IL298193B2 (en) 2020-05-21 2024-01-01 Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
US12444497B2 (en) 2021-05-17 2025-10-14 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
WO2025136970A1 (fr) * 2023-12-20 2025-06-26 Boomerang Medical, Inc. Systèmes et procédés permettant d'ajuster automatiquement et/ou de manière incrémentielle un ou plusieurs paramètres d'administration de signal pour une neuromodulation sacrée

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4408608A (en) * 1981-04-09 1983-10-11 Telectronics Pty. Ltd. Implantable tissue-stimulating prosthesis
US5314457A (en) * 1993-04-08 1994-05-24 Jeutter Dean C Regenerative electrical
US20050137644A1 (en) * 1998-10-26 2005-06-23 Boveja Birinder R. Method and system for vagal blocking and/or vagal stimulation to provide therapy for obesity and other gastrointestinal disorders
US6611715B1 (en) * 1998-10-26 2003-08-26 Birinder R. Boveja Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator
US7076307B2 (en) * 2002-05-09 2006-07-11 Boveja Birinder R Method and system for modulating the vagus nerve (10th cranial nerve) with electrical pulses using implanted and external components, to provide therapy neurological and neuropsychiatric disorders
US6587719B1 (en) * 1999-07-01 2003-07-01 Cyberonics, Inc. Treatment of obesity by bilateral vagus nerve stimulation
US6826428B1 (en) * 2000-04-11 2004-11-30 The Board Of Regents Of The University Of Texas System Gastrointestinal electrical stimulation
US6853858B2 (en) * 2000-05-08 2005-02-08 Brainsgate, Ltd. Administration of anti-inflammatory drugs into the central nervous system
US6609025B2 (en) * 2001-01-02 2003-08-19 Cyberonics, Inc. Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation
US7778711B2 (en) * 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
DE10151650A1 (de) * 2001-10-17 2003-05-08 Univ Eberhard Karls Elektrodenanordnung zur elektrischen Stimulation von biologischem Material sowie Multielektrodenarray zur Verwendung in einer solchen
US7689276B2 (en) * 2002-09-13 2010-03-30 Leptos Biomedical, Inc. Dynamic nerve stimulation for treatment of disorders
US7551964B2 (en) * 2002-03-22 2009-06-23 Leptos Biomedical, Inc. Splanchnic nerve stimulation for treatment of obesity
US7689277B2 (en) * 2002-03-22 2010-03-30 Leptos Biomedical, Inc. Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US7277761B2 (en) * 2002-06-12 2007-10-02 Pacesetter, Inc. Vagal stimulation for improving cardiac function in heart failure or CHF patients
WO2004044947A2 (fr) * 2002-11-14 2004-05-27 Brainsgate Ltd. Circuits de stimulation et commande d'un dispositif medical electronique
US7263405B2 (en) * 2003-08-27 2007-08-28 Neuro And Cardiac Technologies Llc System and method for providing electrical pulses to the vagus nerve(s) to provide therapy for obesity, eating disorders, neurological and neuropsychiatric disorders with a stimulator, comprising bi-directional communication and network capabilities
WO2006078958A2 (fr) * 2005-01-21 2006-07-27 Virginia Technologies, Inc Systeme generateur d'impulsions therapeutiques a haut rendement energetique
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment

Also Published As

Publication number Publication date
AU2008292174B2 (en) 2013-11-07
WO2009027755A1 (fr) 2009-03-05
CA2697622C (fr) 2017-08-01
WO2009027425A3 (fr) 2009-04-16
ZA201001287B (en) 2010-12-29
EP2185235A2 (fr) 2010-05-19
AU2008292174A2 (en) 2010-04-29
AU2008292174A1 (en) 2009-03-05
JP2015006439A (ja) 2015-01-15
CA2697622A1 (fr) 2009-03-05
NZ583619A (en) 2011-12-22
JP2010536523A (ja) 2010-12-02
JP5693225B2 (ja) 2015-04-01
DK2185235T3 (en) 2016-06-20
WO2009027425A2 (fr) 2009-03-05
US20100280569A1 (en) 2010-11-04
IL204110A (en) 2013-05-30

Similar Documents

Publication Publication Date Title
EP2185235B1 (fr) Dispositif de réduction de poids
US7299091B2 (en) Treatment of obesity by bilateral vagus nerve stimulation
US8321030B2 (en) Esophageal activity modulated obesity therapy
US9037244B2 (en) Method and apparatus for electrical stimulation of the pancreatico-biliary system
CA2608017C (fr) Systemes de stimulation electrique des nerfs dans des regions tissulaires adipeuses
US7689276B2 (en) Dynamic nerve stimulation for treatment of disorders
US7236822B2 (en) Wireless electric modulation of sympathetic nervous system
US8185206B2 (en) Electrical stimulation therapy to promote gastric distention for obesity management
US20100241189A1 (en) Nerve Stimulation For Treatment of Obesity, Metabolic Syndrome, and Type 2 Diabetes
US20100145408A1 (en) Splanchnic Nerve Stimulation For Treatment of Obesity
US20100228313A1 (en) Electrical stimulation therapy to promote gastric distention for obesity management
CA2401098C (fr) Traitement de l'obesite par stimulation bilaterale du nerf vague
WO2007087332A2 (fr) Neurostimulation pour traiter l'obésité, le diabète de type 2 et le syndrome métabolique
US20060247717A1 (en) Electrical stimulation of the gastrointestinal tract to regulate motility

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100224

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: VAL-LAILLET, DAVID

Inventor name: BOBILLIER, ERIC

Inventor name: MALBERT, CHARLES-HENRI

Inventor name: BIRABEN, ARNAUD

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130919

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150922

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MALBERT, CHARLES-HENRI

Inventor name: BIRABEN, ARNAUD

Inventor name: BOBILLIER, ERIC

Inventor name: VAL-LAILLET, DAVID

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 780667

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160415

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008042871

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ARNOLD AND SIEDSMA AG, CH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602008042871

Country of ref document: DE

Representative=s name: LAVOIX MUNICH, DE

Ref country code: DK

Ref legal event code: T3

Effective date: 20160617

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160316

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160616

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160617

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160716

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160718

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008042871

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20161219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160616

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160827

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20171123

Year of fee payment: 10

Ref country code: DE

Payment date: 20171030

Year of fee payment: 10

Ref country code: FR

Payment date: 20171031

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20171122

Year of fee payment: 10

Ref country code: GB

Payment date: 20171024

Year of fee payment: 10

Ref country code: AT

Payment date: 20171122

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20080827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160831

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160316

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 780667

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160316

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008042871

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20180831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 780667

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180827

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180827

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180827

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180827